Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 10/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5257153 | 0.91 | VDR (0.57) | VDRTP53MAPTKDM1AMEN1 | |
| SCHEMBL5260961 | 0.86 | KIF11 (0.47) | VDRTP53MAPTKDM1AMEN1 | |
| SCHEMBL5258844 | 0.84 | VDR (0.55) | VDRTP53MAPTKDM1AMEN1 | |
| SCHEMBL5261826 | 0.84 | VDR (0.46) | VDRTP53MAPTTHRBKDM1A | |
| SCHEMBL5262289 | 0.83 | MEN1 (0.43) | VDRTP53MAPTMEN1KMT2A | |
| SCHEMBL27493058 | 0.82 | VDR (0.57) | VDRTP53MAPTMEN1KMT2A | |
| SCHEMBL5256868 | 0.81 | VDR (0.48) | VDRTP53MAPTKDM1AMEN1 | |
| SCHEMBL5261784 | 0.81 | SRC (0.43) | VDRTP53MAPTTHRBMEN1 | |
| SCHEMBL5261671 | 0.80 | MAPT (0.59) | VDRMAPTMEN1KMT2AKDM4E | |
| SCHEMBL25971947 | 0.80 | TP53 (0.70) | VDRTP53MAPTTHRBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261585-B1 | SUBSTITUTED INDOLE MANNICH BASES | GRUENENTHAL GMBH (DE) | 2007-09-26 | — | — | EP | claimed |
| US-7091220-B2 | Substituted indole Mannich bases | GRUENENTHAL GMBH (DE) | 2006-08-15 | — | — | US | claimed |
| CN-1219763-C | Substituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2005-09-21 | — | — | CN | claimed |
| CN-1413192-A | Substituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2003-04-23 | — | — | CN | claimed |
| EP-1261585-A1 | SUBSTITUTED INDOLE MANNICH BASES | Grünenthal GmbH (DE) | 2002-12-04 | — | — | EP | claimed |
| WO-2001047885-A1 | SUBSTITUTED INDOLE MANNICH BASES | Grünenthal GmbH (DE) | 2001-07-05 | — | — | WO | claimed |
| EP-1261585-B1 | SUBSTITUTED INDOLE MANNICH BASES | GRUENENTHAL GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1261585-B1 | SUBSTITUTED INDOLE MANNICH BASES | GRUENENTHAL GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| US-7091220-B2 | Substituted indole Mannich bases | GRUENENTHAL GMBH (DE) | 2006-08-15 | — | — | US | disclosed |
| CN-1219763-C | Substituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2005-09-21 | — | — | CN | disclosed |
| CN-1413192-A | Substituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2003-04-23 | — | — | CN | disclosed |
| US-20030060497-A1 | Subtituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2003-03-27 | — | — | US | disclosed |
| EP-1261585-A1 | SUBSTITUTED INDOLE MANNICH BASES | Grünenthal GmbH (DE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001047885-A1 | SUBSTITUTED INDOLE MANNICH BASES | Grünenthal GmbH (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060497-A1 | Subtituted indole mannich bases | TPH1, IDO1, TPH2 | VDR 2170/4885TP53 1876/4885MAPT 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.